Abstract
The major neuropathologic hallmarks in Alzheimer's disease (AD) consist of neuronal cell loss in selected brain regions, as well as deposition of extracellular senile plaques and intracellular neurofibrillary tangles. Further to these lesions, neuroinflammation is a feature of AD pathology and is thought to contribute to the neurodegeneration. Inflammation clearly occurs in pathologically vulnerable regions of the AD brain, with increased expression of acute phase proteins and pro-inflammatory cytokines. The healthy properties of green tea and apple are linked closely to their content of phenolic compounds. Although the beneficial effects of these compounds are clear, relatively few studies have focused on their anti-inflammatory effects in vivo. The aim of the present study was to test whether daily consumption of a beverage with high antioxidant power combining extracts of green tea and apple over a period of eight months would affect biomarkers of inflammation in AD patients in initial phase, moderate phase and a control group. Administration of the antioxidant beverage (AB) to the three groups did not produce a significant change in serum levels of the antiinflammatory cytokines interleukin-4 and interleukin-10. In contrast, AB decreased serum levels of the pro-inflammatory cytokines interleukin-2 (AD moderate phase vs control group at eight months), interferon-γ (control group vs AD moderate phase and AD initial phase vs placebo beverage at four months) and tumor necrosis factor-α (AD initial phase vs AD moderate phase at four months). AB was more effective against inflammation in the early period of AD, and could be used as a natural complementary therapy to alleviate or improve symptoms of inflammation in early stages of AD.
Keywords: Alzheimer's disease, antioxidant, apple, beverage, cytokines, green tea, inflammation.
CNS & Neurological Disorders - Drug Targets
Title:Serum Cytokine Profile in Alzheimer's Disease Patients After Ingestion of an Antioxidant Beverage
Volume: 12 Issue: 8
Author(s): J.M. Rubio-Perez and J.M. Morillas-Ruiz
Affiliation:
Keywords: Alzheimer's disease, antioxidant, apple, beverage, cytokines, green tea, inflammation.
Abstract: The major neuropathologic hallmarks in Alzheimer's disease (AD) consist of neuronal cell loss in selected brain regions, as well as deposition of extracellular senile plaques and intracellular neurofibrillary tangles. Further to these lesions, neuroinflammation is a feature of AD pathology and is thought to contribute to the neurodegeneration. Inflammation clearly occurs in pathologically vulnerable regions of the AD brain, with increased expression of acute phase proteins and pro-inflammatory cytokines. The healthy properties of green tea and apple are linked closely to their content of phenolic compounds. Although the beneficial effects of these compounds are clear, relatively few studies have focused on their anti-inflammatory effects in vivo. The aim of the present study was to test whether daily consumption of a beverage with high antioxidant power combining extracts of green tea and apple over a period of eight months would affect biomarkers of inflammation in AD patients in initial phase, moderate phase and a control group. Administration of the antioxidant beverage (AB) to the three groups did not produce a significant change in serum levels of the antiinflammatory cytokines interleukin-4 and interleukin-10. In contrast, AB decreased serum levels of the pro-inflammatory cytokines interleukin-2 (AD moderate phase vs control group at eight months), interferon-γ (control group vs AD moderate phase and AD initial phase vs placebo beverage at four months) and tumor necrosis factor-α (AD initial phase vs AD moderate phase at four months). AB was more effective against inflammation in the early period of AD, and could be used as a natural complementary therapy to alleviate or improve symptoms of inflammation in early stages of AD.
Export Options
About this article
Cite this article as:
Rubio-Perez J.M. and Morillas-Ruiz J.M., Serum Cytokine Profile in Alzheimer's Disease Patients After Ingestion of an Antioxidant Beverage, CNS & Neurological Disorders - Drug Targets 2013; 12 (8) . https://dx.doi.org/10.2174/18715273113129990075
DOI https://dx.doi.org/10.2174/18715273113129990075 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cognitive Dysfunction in Depression – Pathophysiology and Novel Targets
CNS & Neurological Disorders - Drug Targets NGF-Cholinergic Dependency in Brain Aging, MCI and Alzheimers Disease
Current Alzheimer Research Enteric Ecosystem Disruption in Autism Spectrum Disorder: Can the Microbiota and Macrobiota be Restored?
Current Pharmaceutical Design 3,4-Dihydrospiro[piperidine-4,2-(1H)quinoline] Derivatives as New Antioxidant Agents with Acetylcholinesterase Inhibitory Property
Letters in Drug Design & Discovery Role of Ligand-Based Drug Design Methodologies toward the Discovery of New Anti- Alzheimer Agents: Futures Perspectives in Fragment-Based Ligand Design
Current Medicinal Chemistry Low 25OH Vitamin D2 Levels Found in Untreated Alzheimer’s Patients, Compared to Acetylcholinesterase-Inhibitor Treated and Controls
Current Alzheimer Research Modulation of Apoptosis in Acute Ischemic Stroke as Treatment Challenges
Current Immunology Reviews (Discontinued) The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets “Vascular Incontinence” and Normal-Pressure Hydrocephalus: Two Commonsources of Elderly Incontinence with Brain Etiologies
Current Drug Therapy Pneumonia in the Elderly
Current Respiratory Medicine Reviews Covid-19 in Man: A Very Dangerous Affair
Endocrine, Metabolic & Immune Disorders - Drug Targets Genetic Variations in CHRNA7 or CHRFAM7 and Susceptibility to Dementia
Current Drug Targets Vasoactive Intestinal Peptide in Neurodevelopmental Disorders:Therapeutic Potential
Current Pharmaceutical Design Molecular Imaging in the Default Mode Network
Current Molecular Imaging (Discontinued) Allosteric Enhancers for A1 Adenosine Receptor
Mini-Reviews in Medicinal Chemistry Development of Nucleic Acid Drugs for Neurological Disorders
Current Topics in Medicinal Chemistry The Premature Lottery in the Canadian Grey Zones
Current Pediatric Reviews Editorial [Hot Topic: Prolyl Oligopeptidase in Brain Function and Dysfunction (Guest Editor: J. Arturo Garcia-Horsman)]
CNS & Neurological Disorders - Drug Targets Current Role and Future Perspectives of Radioiodinated MIBG in the Evaluation of Dementia with Lewy Bodies
Current Radiopharmaceuticals Association of Mean Platelet Volume with Hypertension in Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued)